Skip to main content

Lung Cancer

New Understandings and Therapies

  • Book
  • © 2021

Overview

  • Highlight recent updates in lung cancer management, both NSCLC and SCLC.
  • Focus on translational approaches in understanding resistance biology to inform clinical management in patients treated with immuno and targeted therapies
  • Provide the latest update on understanding and use of biomarkers in the tumor macro and microenvironment and circulating in blood
  • Focus on changing concepts and use of immunotherapy and radiotherapy in lung cancer as well as in patients with CNS involvement

Part of the book series: Current Cancer Research (CUCR)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

Keywords

About this book

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach.  For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment.  Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Editors and Affiliations

  • Yale Comprehensive Cancer Center, Yale University, New Haevn, USA

    Anne C. Chiang, Roy S. Herbst

About the editors

Anne Chiang is an Associate Professor at Yale University’s School of Medicine and a member of the Yale Cancer Center’s Developmental Therapeutics and Thoracic Oncology Programs.  She serves as Chief Network Officer and the Deputy Chief Medical Officer at the Smilow Cancer Hospital at Yale.  Chiang earned an MD from Weill Cornell Medical College, a Ph.D. in Molecular Genetics from Harvard University and an A.B. from Princeton University in Molecular Biology.

 

Roy Herbst is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University’s School of Medicine. He serves as Chief of Medical Oncology and the Associate Director for Translational Research at the Yale Cancer Center. Herbst earned his B.S. and M.S. degrees at Yale, his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University. He has authored more than 275 publications, including peer-reviewedjournal articles, abstracts, and book chapters.

Bibliographic Information

  • Book Title: Lung Cancer

  • Book Subtitle: New Understandings and Therapies

  • Editors: Anne C. Chiang, Roy S. Herbst

  • Series Title: Current Cancer Research

  • DOI: https://doi.org/10.1007/978-3-030-74028-3

  • Publisher: Humana Cham

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Nature Switzerland AG 2021

  • Hardcover ISBN: 978-3-030-74027-6Published: 01 October 2021

  • Softcover ISBN: 978-3-030-74030-6Published: 02 October 2022

  • eBook ISBN: 978-3-030-74028-3Published: 30 September 2021

  • Series ISSN: 2199-2584

  • Series E-ISSN: 2199-2592

  • Edition Number: 1

  • Number of Pages: VI, 264

  • Number of Illustrations: 1 b/w illustrations, 16 illustrations in colour

  • Topics: Cancer Research, Molecular Medicine, Oncology

Publish with us